Carmel Awadallah, MD

Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access.

The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.